Replimune Group Investor Relations Material
Latest events
Study Result
Replimune Group
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Replimune Group Inc
Access all reports
Replimune Group Inc. is a biotechnology company focused on the development of oncolytic immunotherapies for the treatment of cancer. The company leverages its proprietary Immulytic platform to engineer viruses that selectively replicate within tumors, stimulating an immune response to attack the cancer cells. Replimune's therapies are designed to be used in combination with other immuno-oncology treatments to enhance their effectiveness. The company targets various forms of cancer, aiming to improve outcomes for patients with difficult-to-treat malignancies. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Replimune Group Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Replimune Group Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Replimune Group Inc
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
REPL
Country
🇺🇸 United States